Utilization of Collaborative Practice Agreements between Physicians and Pharmacists as a Mechanism to Increase Capacity to Care for Hematopoietic Stem Cell Transplant Recipients

Julianna A. Merten, Jamie F. Shapiro, Alison M. Gulbis, Kamakshi V. Rao, Joseph Bubalo, Scott Lanum, Ashley Morris Engemann, Sepideh Shayani, Casey Williams, Helen Leather, Tracey Walsh-Chocolaad

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    Survival after hematopoietic stem cell transplantation (HSCT) has improved and the number of allogeneic HSCTs performed annually in the United States is expected to reach 10,000 by 2015. The National Marrow Donor Program created the System Capacity Initiative to formulate mechanisms to care for the growing number of HSCT recipients. One proposed method to increase capacity is utilization of pharmacists to manage drug therapy via collaborative practice agreements (CPAs). Pharmacists have managed drug therapy in oncology patients with CPAs for decades; however, there are limited HSCT centers that employ this practice. Engaging in collaborative practice and billing agreements with credentialed pharmacists to manage therapeutic drug monitoring, chronic medical conditions, and supportive care in HSCT recipients may be cost-effective and enable physicians to spend more time on new or more complex patients. The goal of this paper is to provide a framework for implementation of a CPA and address how it may improve HSCT program capacity.

    Original languageEnglish (US)
    Pages (from-to)509-518
    Number of pages10
    JournalBiology of Blood and Marrow Transplantation
    Volume19
    Issue number4
    DOIs
    StatePublished - Apr 2013

    Fingerprint

    Hematopoietic Stem Cell Transplantation
    Hematopoietic Stem Cells
    Pharmacists
    Physicians
    Transplants
    Drug Therapy
    Drug Monitoring
    Bone Marrow
    Transplant Recipients
    Tissue Donors
    Costs and Cost Analysis
    Survival

    Keywords

    • Collaborative drug therapy management
    • Hematopoietic cell transplantation
    • Medication Therapy Management
    • National Marrow Donor Program
    • Pharmaceutical services
    • Physician capacity

    ASJC Scopus subject areas

    • Transplantation
    • Hematology

    Cite this

    Utilization of Collaborative Practice Agreements between Physicians and Pharmacists as a Mechanism to Increase Capacity to Care for Hematopoietic Stem Cell Transplant Recipients. / Merten, Julianna A.; Shapiro, Jamie F.; Gulbis, Alison M.; Rao, Kamakshi V.; Bubalo, Joseph; Lanum, Scott; Engemann, Ashley Morris; Shayani, Sepideh; Williams, Casey; Leather, Helen; Walsh-Chocolaad, Tracey.

    In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 4, 04.2013, p. 509-518.

    Research output: Contribution to journalArticle

    Merten, JA, Shapiro, JF, Gulbis, AM, Rao, KV, Bubalo, J, Lanum, S, Engemann, AM, Shayani, S, Williams, C, Leather, H & Walsh-Chocolaad, T 2013, 'Utilization of Collaborative Practice Agreements between Physicians and Pharmacists as a Mechanism to Increase Capacity to Care for Hematopoietic Stem Cell Transplant Recipients', Biology of Blood and Marrow Transplantation, vol. 19, no. 4, pp. 509-518. https://doi.org/10.1016/j.bbmt.2012.12.022
    Merten, Julianna A. ; Shapiro, Jamie F. ; Gulbis, Alison M. ; Rao, Kamakshi V. ; Bubalo, Joseph ; Lanum, Scott ; Engemann, Ashley Morris ; Shayani, Sepideh ; Williams, Casey ; Leather, Helen ; Walsh-Chocolaad, Tracey. / Utilization of Collaborative Practice Agreements between Physicians and Pharmacists as a Mechanism to Increase Capacity to Care for Hematopoietic Stem Cell Transplant Recipients. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 4. pp. 509-518.
    @article{c1ac1cfa87284b4db5cffe755b3f3611,
    title = "Utilization of Collaborative Practice Agreements between Physicians and Pharmacists as a Mechanism to Increase Capacity to Care for Hematopoietic Stem Cell Transplant Recipients",
    abstract = "Survival after hematopoietic stem cell transplantation (HSCT) has improved and the number of allogeneic HSCTs performed annually in the United States is expected to reach 10,000 by 2015. The National Marrow Donor Program created the System Capacity Initiative to formulate mechanisms to care for the growing number of HSCT recipients. One proposed method to increase capacity is utilization of pharmacists to manage drug therapy via collaborative practice agreements (CPAs). Pharmacists have managed drug therapy in oncology patients with CPAs for decades; however, there are limited HSCT centers that employ this practice. Engaging in collaborative practice and billing agreements with credentialed pharmacists to manage therapeutic drug monitoring, chronic medical conditions, and supportive care in HSCT recipients may be cost-effective and enable physicians to spend more time on new or more complex patients. The goal of this paper is to provide a framework for implementation of a CPA and address how it may improve HSCT program capacity.",
    keywords = "Collaborative drug therapy management, Hematopoietic cell transplantation, Medication Therapy Management, National Marrow Donor Program, Pharmaceutical services, Physician capacity",
    author = "Merten, {Julianna A.} and Shapiro, {Jamie F.} and Gulbis, {Alison M.} and Rao, {Kamakshi V.} and Joseph Bubalo and Scott Lanum and Engemann, {Ashley Morris} and Sepideh Shayani and Casey Williams and Helen Leather and Tracey Walsh-Chocolaad",
    year = "2013",
    month = "4",
    doi = "10.1016/j.bbmt.2012.12.022",
    language = "English (US)",
    volume = "19",
    pages = "509--518",
    journal = "Biology of Blood and Marrow Transplantation",
    issn = "1083-8791",
    publisher = "Elsevier Inc.",
    number = "4",

    }

    TY - JOUR

    T1 - Utilization of Collaborative Practice Agreements between Physicians and Pharmacists as a Mechanism to Increase Capacity to Care for Hematopoietic Stem Cell Transplant Recipients

    AU - Merten, Julianna A.

    AU - Shapiro, Jamie F.

    AU - Gulbis, Alison M.

    AU - Rao, Kamakshi V.

    AU - Bubalo, Joseph

    AU - Lanum, Scott

    AU - Engemann, Ashley Morris

    AU - Shayani, Sepideh

    AU - Williams, Casey

    AU - Leather, Helen

    AU - Walsh-Chocolaad, Tracey

    PY - 2013/4

    Y1 - 2013/4

    N2 - Survival after hematopoietic stem cell transplantation (HSCT) has improved and the number of allogeneic HSCTs performed annually in the United States is expected to reach 10,000 by 2015. The National Marrow Donor Program created the System Capacity Initiative to formulate mechanisms to care for the growing number of HSCT recipients. One proposed method to increase capacity is utilization of pharmacists to manage drug therapy via collaborative practice agreements (CPAs). Pharmacists have managed drug therapy in oncology patients with CPAs for decades; however, there are limited HSCT centers that employ this practice. Engaging in collaborative practice and billing agreements with credentialed pharmacists to manage therapeutic drug monitoring, chronic medical conditions, and supportive care in HSCT recipients may be cost-effective and enable physicians to spend more time on new or more complex patients. The goal of this paper is to provide a framework for implementation of a CPA and address how it may improve HSCT program capacity.

    AB - Survival after hematopoietic stem cell transplantation (HSCT) has improved and the number of allogeneic HSCTs performed annually in the United States is expected to reach 10,000 by 2015. The National Marrow Donor Program created the System Capacity Initiative to formulate mechanisms to care for the growing number of HSCT recipients. One proposed method to increase capacity is utilization of pharmacists to manage drug therapy via collaborative practice agreements (CPAs). Pharmacists have managed drug therapy in oncology patients with CPAs for decades; however, there are limited HSCT centers that employ this practice. Engaging in collaborative practice and billing agreements with credentialed pharmacists to manage therapeutic drug monitoring, chronic medical conditions, and supportive care in HSCT recipients may be cost-effective and enable physicians to spend more time on new or more complex patients. The goal of this paper is to provide a framework for implementation of a CPA and address how it may improve HSCT program capacity.

    KW - Collaborative drug therapy management

    KW - Hematopoietic cell transplantation

    KW - Medication Therapy Management

    KW - National Marrow Donor Program

    KW - Pharmaceutical services

    KW - Physician capacity

    UR - http://www.scopus.com/inward/record.url?scp=84875488797&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84875488797&partnerID=8YFLogxK

    U2 - 10.1016/j.bbmt.2012.12.022

    DO - 10.1016/j.bbmt.2012.12.022

    M3 - Article

    C2 - 23419976

    AN - SCOPUS:84875488797

    VL - 19

    SP - 509

    EP - 518

    JO - Biology of Blood and Marrow Transplantation

    JF - Biology of Blood and Marrow Transplantation

    SN - 1083-8791

    IS - 4

    ER -